Sign In
Buy MGTX
$9.39
+0.150 (+1.62%)
At Close: Jun 03, 2026
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:01am, Wednesday, 05'th Nov 2025
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?
09:21am, Wednesday, 22'nd Oct 2025
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
08:00am, Tuesday, 07'th Oct 2025
LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhib
MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital
03:48am, Thursday, 25'th Sep 2025
MeiraGTx is a clinical-stage gene therapy biotech with end-to-end GMP. Its late-stage assets include AAV-AIPL1, AAV-AQP1, and Bota-Vec. AAV-AQP1 is in pivotal Phase 2 trials under the FDA's RMAT desig
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates
10:11am, Thursday, 14'th Aug 2025
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.76 per share a year ago.
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
08:00am, Thursday, 14'th Aug 2025
- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RI
3 Promising Genomics Stocks to Keep an Eye On in 2025
09:06am, Friday, 27'th Jun 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
04:30pm, Tuesday, 13'th May 2025
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's T
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
10:15am, Tuesday, 13'th May 2025
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.77 per share a year ago.
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
08:00am, Tuesday, 13'th May 2025
- Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the bene
The global cone rod dystrophy market, valued at US$131.29 million in 2024, is projected to reach US$177.59 million by 2030, growing at a CAGR of 5.33%. Key drivers include advancements in gene therapi
MeiraGTx Holdings: Gaining Regulatory Focus
10:50am, Tuesday, 25'th Mar 2025
MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson's Disease, and xerostomia, with multiple assets in advanced clinical stages showing promising efficacy and safety data. MGTX uses
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars
09:51am, Thursday, 13'th Mar 2025
On Thursday, MeiraGTx Holdings plc MGTX announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clini
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
08:00am, Thursday, 13'th Mar 2025
- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 millio
